Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other 1 Gastrointestinal 1

Conditions

Obesity 9 Endometrial Neoplasms 4 Prostatic Neoplasms 2 Overweight 2 Endometrial Hyperplasia 2 Diabetes Mellitus 2 Breast Neoplasms 2 Weight Loss 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Polycystic Ovary Syndrome 1 Opioid-Related Disorders 1 Metabolic Syndrome 1 Lymphoma, Follicular 1 Insulin Resistance 1 Inflammation 1 Hyperplasia 1 Dyslipidemias 1 Colorectal Neoplasms 1

Interventions

Bevacizumab 119 Fluorouracil 91 Leucovorin 83 Cetuximab 83 Oxaliplatin 80 pembrolizumab 70 Irinotecan 67 Nivolumab 46 Capecitabine 43 Specimen Handling 40 regorafenib 30 Folfox protocol 29 trifluridine tipiracil drug combination 28 Magnetic Resonance Spectroscopy 27 Biopsy 27 Panitumumab 26 Standard of Care 25 HMPL-013 25 IFL protocol 21 Gemcitabine 20 Blood Specimen Collection 19 atezolizumab 18 Trifluridine 18 Cisplatin 18 tislelizumab 17 balstilimab 16 Colonoscopy 16 Carboplatin 16 encorafenib 15 Paclitaxel 14

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Colorectal Neoplasms × Tirzepatide × 1 year × Clear all

NCT07095517 2026-02-27

PROSPECT

Massachusetts General Hospital

Phase 1 Recruiting

GastrointestinalOther

Obesity, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡